Rangeley Capital’s Pliant Therapeutics PLRX Stock Holding History

Rangeley Capital’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$257K	Hold	225,000	–	–	0.23%	103
2026 Q1	$284K	Hold	225,000	–	–	0.28%	75
2025 Q4	$275K	Buy	225,000 +164,780	+274%	+$248K	0.23%	76
2025 Q3	$89.1K	Hold	60,220	–	–	0.08%	112
2025 Q2	$69.9K	Buy	60,220 +10,220	+20%	+$14.4K	0.08%	59
2025 Q1	$67.5K	Buy	+50,000	New	+$304K	0.07%	74

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Rangeley Capital's PLRX Position: Q2 2026 in Review

Rangeley Capital held its Pliant Therapeutics (PLRX) position steady in Q2 2026 at 225,000 shares worth $257K. The position accounts for 0.23% of the portfolio, ranked #103.

Rangeley Capital first reported a position in PLRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $284K in Q1 2026. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Rangeley Capital held 225,000 shares of Pliant Therapeutics worth $257K as of Q2 2026.
Rangeley Capital left its Pliant Therapeutics share count unchanged in Q2 2026.
Pliant Therapeutics made up 0.23% of Rangeley Capital's portfolio in Q2 2026, its #103 holding.
Rangeley Capital first reported a position in Pliant Therapeutics in Q1 2025 and has held it in 6 quarters since.
Rangeley Capital's Pliant Therapeutics position peaked at $284K in Q1 2026.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.